Antineoplastic Combined Chemotherapy Protocols
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in the URMC Research Network by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publication.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Scosyrev E, Messing EM. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? BJU Int. 2011 Sep; 108(5):700.
-
Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong FL, Tew WP. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011 Sep 1; 29(25):3457-65.
-
Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, Dewald G, Bennett JM, Paietta EM, Byrd JC, Hussein MA, Appelbaum FR, Larson RA, Litzow MR, Tallman MS. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood. 2011 Sep 29; 118(13):3525-7.
-
Dao H, Barr PM, Honda K. Regression of CD30+ cutaneous anaplastic large-cell lymphoma with denileukin diftitox. J Am Acad Dermatol. 2011 Jun; 64(6):e123-5.
-
Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, Lipshultz SE, Camitta BM. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood. 2011 Jul 28; 118(4):874-83.
-
Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011 Mar 10; 117(10):2807-12.
-
Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, de Vere White RW, Vogelzang NJ, Trump DL, Natale RB, Tangen CM, Crawford ED, Thompson IM. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int. 2011 Sep; 108(5):693-9.
-
Jansson J, Hsu YC, Kuzin II, Campbell A, Mullen CA. Acute lymphoblastic leukemia cells that survive combination chemotherapy in vivo remain sensitive to allogeneic immune effects. Leuk Res. 2011 Jun; 35(6):800-7.
-
Phillips GL, Bernstein SH, Liesveld JL, Abboud CN, Becker MW, Constine LS, Ifthikharuddin JJ, Loughner JE, Milner LA, Vesole DH, Friedberg JW. A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. Biol Blood Marrow Transplant. 2011 Jul; 17(7):1033-42.
-
Casulo C, Horwitz S. Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting? Curr Oncol Rep. 2010 Nov; 12(6):374-82.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
|
